Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People Briefs

This article was originally published in The Gray Sheet

Executive Summary

Cohera Medical CEO named AdvaMed Accel chair; Trovagene sacks CEO and CFO over precision medicine dispute; OraSure Technologies appoints Eamonn Hobbs to board; DNA Diagnostics Center names its president and CEO; Lantheus Holdings taps CFO; Omcron gets new president and CEO.

You may also be interested in...



People Briefs: NuVasive, Delcath, Boston Scientific, Silk Road, Si-Bone

NuVasive and Delcath Systems appoint CEOs. Boston Scientific Corp. names senior medical director, rhythm management. Silk Road Medical Inc. appoints executive VP, global sales. Si-Bone taps CFO.

UK Parliamentarians Call For A New, Internationally Competitive Pricing System

Much-needed investment could be lost if the “uncompetitive” sales rebate rate is not reduced as part of talks on a new UK drug pricing scheme, some parliamentarians are warning.

AESGP Annual Meeting: Sustainability Optional Now, But Not For Long, Warns Haleon

European consumer health companies today have the luxury of voluntarily setting sustainability goals. But with regulations looming and pressure from retailers and consumers mounting, such requirements will soon be mandatory, Haleon’s Joe Muscat warned at the recent AESGP Annual Meeting in Paris, France. To ride the climate wave, while achieving their objectives, OTC firms need to work together, he explained.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034646

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel